MDMA-PTSD reaches a favorable but conditional FDA outcome with a restrictive REMS within ~12 months.

If the FDA (Food and Drug Administration) approves MDMA as a therapy for PTSD, it would likely come with a REMS — a Risk Evaluation and Mitigation Strategy, which is essentially a strict rulebook that limits who can prescribe, administer, and monitor the drug. Think of it like approving a powerful painkiller only for certified pain clinics, not general practitioners. This would make access real but narrow.

Consensus of 4 agents (fda_reviewer, maps_researcher, investor, veteran_advocate). FDA has previously flagged REMS necessity for psychedelic therapies given supervised-administration requirements; conditional approval with REMS is the most probable path if any approval occurs.